Dr. Pablo Sanchez is a medical fellow at Stanford University. He earned a degree in physiology at The University of Arizona and received his M.D. from The University of Arizona College of Medicine, in Tucson. He completed Internal Medicine training at Brigham & Women's Hospital/Harvard Medical School, and served as Chief Resident from 2018-2019. During residency, his research focused on clinical outcomes of the complex patient composition in the modern Cardiac Intensive Care Unit. He completed Cardiovascular Medicine fellowship at Stanford and served as Chief Fellow from 2021-2022. He is interested in cardio-pulmonary interactions in Acute Respiratory Distress Syndrome (ARDS). Under the tutelage of Dr. Angela Rogers (Pulmonary Medicine Division) and Dr. Euan Ashley (Cardiovascular Medicine Division), he plans to integrate immune-metabolic biomarker and echocardiographic profiling to identify cardiac dysfunction in ARDS. He receives funding from the National Institutes of Health through the Ruth L. Kirschstein National Research Service Award (NRSA, F32) and Loan Repayment Award. He is pursuing additional fellowship training in critical care medicine.

Clinical Focus

  • Fellow
  • Cardiovascular Medicine
  • Critical Care

Honors & Awards

  • Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32), National Institutes of Health (2022)
  • Clinical Research Loan Repayment Program, National Institutes of Health (2022)
  • Stanford Pulmonary Biology Training Program (T32), National Institutes of Health (2022)
  • AHA CLCD Minority Travel Grant, American Heart Association (2019)
  • Resident Mentor Award - Internal Medicine, Brigham and Women's Hospital/Harvard Medical School (2017)
  • Graduating Honors - Research with Distinction, University of Arizona College of Medicine - Tucson (2015)
  • Medical Student of the Year, American College of Physicians - Arizona Chapter (2014)
  • Gold Humanism Honor Society (GHHS), University of Arizona College of Medicine - Tucson (2014)
  • Alpha Omega Alpha Honor Medical Society (AOA), University of Arizona College of Medicine - Tucson (2014)
  • First Place Medical Student Poster, American College of Physicians - Arizona Chapter (2014)
  • Margarito Chavez Grant, Sarver Heart Center (2013)
  • Medical Student Leadership Award and Scholarship, Arizona Latino Medical Association (2013)
  • Community Service Award, Latino Medical Student Association (2012)
  • Office of Outreach and Multicultural Affairs Leadership Award, University of Arizona College of Medicine - Tucson (2012)
  • Van Winkle Award for Excellence in Surgical Research, University of Arizona College of Medicine - Tucson (2011)

Professional Education

  • Fellowship, Stanford University, Critical Care Medicine (2024)
  • Chief Fellow, Stanford University, Cardiovascular Medicine (2021)
  • Fellowship, Stanford University, Cardiovascular Medicine (2022)
  • Board Certification, American Board of Internal Medicine, Internal Medicine (2019)
  • Chief Resident, Brigham and Women's Hospital, Harvard Medical School, Internal Medicine (2018)
  • Residency, Brigham and Women's Hospital, Harvard Medical School, Internal Medicine (2018)
  • Internship, Brigham and Women's Hospital, Harvard Medical School, Internal Medicine (2016)
  • M.D. with honors, The University of Arizona College of Medicine - Tucson, Medicine (2015)
  • B.S., The University of Arizona, Physiology (2009)

All Publications

  • Identifying consistent echocardiographic thresholds for risk stratification in pulmonary arterial hypertension. Pulmonary circulation Celestin, B. E., Bagherzadeh, S. P., Ichimura, K., Santana, E. J., Sanchez, P. A., Tobore, T., Hemnes, A. R., Noordegraaf, A. V., Salerno, M., Zamanian, R. T., Sweatt, A. J., Haddad, F. 2024; 14 (2): e12361


    Several indices of right heart remodeling and function have been associated with survival in pulmonary arterial hypertension (PAH). Outcome analysis and physiological relationships between variables may help develop a consistent grading system. Patients with Group 1 PAH followed at Stanford Hospital who underwent right heart catheterization and echocardiography within 2 weeks were considered for inclusion. Echocardiographic variables included tricuspid annular plane systolic excursion (TAPSE), right ventricular (RV) fractional area change (RVFAC), free wall strain (RVFWS), RV dimensions, and right atrial volumes. The main outcome consisted of death or lung transplantation at 5 years. Mathematical relationships between variables were determined using weighted linear regression and severity thresholds for were calibrated to a 20% 1-year mortality risk. PAH patients (n=223) had mean (SD) age of 48.1 (14.1) years, most were female (78%), with a mean pulmonary arterial pressure of 51.6 (13.8) mmHg and pulmonary vascular resistance index of 22.5(6.3) WU/m2. Measures of right heart size and function were strongly related to each other particularly RVFWS and RVFAC (R 2=0.82, p<0.001), whereas the relationship between TAPSE and RVFWS was weaker (R 2=0.28, p<0.001). Death or lung transplantation at 5 years occurred in 78 patients (35%). Guided by outcome analysis, we ascertained a uniform set of parameter thresholds for grading the severity of right heart adaptation in PAH. Using these quantitative thresholds, we, then, validated the recently reported REVEAL-echo score (AUC 0.68, p<0.001). This study proposes a consistent echocardiographic grading system for right heart adaptation in PAH guided by outcome analysis.

    View details for DOI 10.1002/pul2.12361

    View details for PubMedID 38800494

  • Variation in risk-adjusted Cardiac Intensive Care Unit (CICU) length of stay and the association with in-hospital mortality: an analysis from the Critical Care Cardiology Trials Network (CCCTN) registry. American heart journal Koerber, D. M., Katz, J. N., Bohula, E., Park, J. G., Dodson, M. W., Gerber, D. A., Hillerson, D., Liu, S., Pierce, M. J., Prasad, R., Rose, S. W., Sanchez, P. A., Shaw, J., Wang, J., Jentzer, J. C., Kristin Newby, L., Daniels, L. B., Morrow, D. A., van Diepen, S. 2024


    Previous studies have suggested that there is wide variability in cardiac intensive care unit (CICU) length of stay (LOS); however, these studies are limited by the absence of detailed risk assessment at the time of admission. Thus, we evaluated inter-hospital differences in CICU LOS, and the association between LOS and in-hospital mortality.Using data from the Critical Care Cardiology Trials Network (CCCTN) registry, we included 22,862 admissions between 2017 and 2022 from 35 primarily tertiary and quaternary CICUs that captured consecutive admissions in annual two-month snapshots. The primary analysis compared inter-hospital differences in CICU LOS, as well as the association between CICU LOS and all-cause in-hospital mortality using a Fine and Gray competing risk model.The overall median CICU LOS was 2.2 (1.1-4.8) days, and the median hospital LOS was 5.9 (2.8-12.3) days. Admissions in the longest tertile of LOS tended to be younger with higher rates of pre-existing comorbidities, and had higher Sequential Organ Failure Assessment (SOFA) scores, as well as higher rates of mechanical ventilation, intravenous vasopressor use, mechanical circulatory support, and renal replacement therapy. Unadjusted all-cause in-hospital mortality was 9.3%, 6.7%, and 13.4% in the lowest, intermediate, and highest CICU LOS tertiles. In a competing risk analysis, individual patient CICU LOS was correlated (r2=0.31) with a higher risk of 30-day in-hospital mortality. The relationship remained significant in admissions with heart failure, ST-elevation myocardial infarction and non-ST segment elevation myocardial infarction.In a large registry of academic CICUs, we observed significant variation in CICU LOS and report that LOS is independently associated with all-cause in-hospital mortality. These findings could potentially be used to improve CICU resource utilization planning and refine risk prognostication in critically ill cardiovascular patients.

    View details for DOI 10.1016/j.ahj.2024.02.010

    View details for PubMedID 38369218

  • The Echocardiographic Evaluation of the Right Heart: Current and Future Advances. Current cardiology reports O'Donnell, C., Sanchez, P. A., Celestin, B., McConnell, M. V., Haddad, F. 2023


    PURPOSE OF REVIEW: To discuss physiologic and methodologic advances in the echocardiographic assessment of right heart (RH) function, including the emergence of artificial intelligence (AI) and point-of-care ultrasound.RECENT FINDINGS: Recent studies have highlighted the prognostic value of right ventricular (RV) longitudinal strain, RV end-systolic dimensions, and right atrial (RA) size and function in pulmonary hypertension and heart failure. While RA pressure is a central marker of right heart diastolic function, the recent emphasis on venous excess imaging (VExUS) has provided granularity to the systemic consequences of RH failure. Several methodological advances are also changing the landscape of RH imaging including post-processing 3D software to delineate the non-longitudinal (radial, anteroposterior, and circumferential) components of RV function, as well as AI segmentation- and non-segmentation-based quantification. Together with recent guidelines and advances in AI technology, the field is shifting from specific RV functional metrics to integrated RH disease-specific phenotypes. A modern echocardiographic evaluation of RH function should focus on the entire cardiopulmonary venous unit-from the venous to the pulmonary arterial system. Together, a multi-parametric approach, guided by physiology and AI algorithms, will help define novel integrated RH profiles for improved disease detection and monitoring. Advances in right heart echocardiography will incorporate a physiologic, multi-parametric approach that is augmented by deep learning to develop integrated right heart phenotypes. Ao Aorta, LV left ventricle, RA right atria, RV right ventricle, PA pulmonary artery.

    View details for DOI 10.1007/s11886-023-02001-6

    View details for PubMedID 38041726

  • Right Ventricular Dysfunction Patterns Among Patients with COVID-19 in the Intensive Care Unit - a Retrospective Cohort Analysis. Annals of the American Thoracic Society Sanchez, P. A., O'Donnell, C. T., Francisco, N., Santana, E. J., Moore, A. R., Pacheco-Navarro, A., Roque, J., Lebold, K. M., Parmer, C. M., Pienkos, S. M., Celestin, B. E., Levitt, J. E., Collins, W. J., Lanspa, M. J., Ashley, E. A., Wilson, J. G., Haddad, F., Rogers, A. J. 2023


    Right ventricular (RV) dysfunction is common among patients hospitalized with COVID-19; however, its epidemiology may depend on the echocardiographic parameters used to define it.To evaluate the prevalence of abnormalities in three common echocardiographic parameters of RV function among COVID-19 patients admitted to the intensive care unit, as well as the effect of RV dilatation on differential parameter abnormality and the association of RV dysfunction with 60-day mortality.Retrospective cohort study of COVID-19 ICU patients between March 4th,2020 to March 4th, 2021, who received a transthoracic echocardiogram within 48 hours before to at most 7 days after ICU admission. RV dysfunction and dilatation respectively defined by guideline thresholds for tricuspid annular plane systolic excursion (TAPSE), RV fractional area change (RVFAC), RV free wall longitudinal strain (RVFWS), and RV basal dimension or RV end-diastolic area. Association of RV dysfunction with 60-day mortality assessed through logistic regression adjusting for age, prior history of congestive heart failure, invasive ventilation at time of TTE and APACHE II score.116 patients were included, of which 69% had RV dysfunction by > 1 parameter and 36.3% of these had RV dilatation. The three most common patterns of RV dysfunction included: Presence of 3 abnormalities, the combination of abnormal RVFWS and TAPSE, and isolated TAPSE abnormality. Patients with RV dilatation had worse RVFAC (24% vs 36%, p = 0.001), worse RVFWS (16.3% vs 19.1%, p = 0.005), higher RVSP (45mmHg vs 31mmHg, p = 0.001) but similar TAPSE (13mm vs 13mm, p = 0.30) compared to those with normal RV size. After multivariable adjustment, 60-day mortality was significantly associated with RV dysfunction (OR 2.91, 95% CI 1.01 - 9.44), as was the presence of at least 2 parameter abnormalities.ICU patients with COVID-19 had significant heterogeneity in RV function abnormalities present with different patterns associated with RV dilatation. RV dysfunction by any parameter was associated with increased mortality. Therefore, a multiparameter evaluation may be critical in recognizing RV dysfunction in COVID-19.

    View details for DOI 10.1513/AnnalsATS.202303-235OC

    View details for PubMedID 37478340

  • Critically Ill Patients With Cardiac Dysfunction and the Rashomon Effect Chest Critical Care Sanchez, P. A., Lanspa, M. J. 2023
  • Multimodal deep learning enhances diagnostic precision in left ventricular hypertrophy. European heart journal. Digital health Soto, J. T., Weston Hughes, J., Sanchez, P. A., Perez, M., Ouyang, D., Ashley, E. A. 2022; 3 (3): 380-389


    Aims: Determining the aetiology of left ventricular hypertrophy (LVH) can be challenging due to the similarity in clinical presentation and cardiac morphological features of diverse causes of disease. In particular, distinguishing individuals with hypertrophic cardiomyopathy (HCM) from the much larger set of individuals with manifest or occult hypertension (HTN) is of major importance for family screening and the prevention of sudden death. We hypothesized that an artificial intelligence method based joint interpretation of 12-lead electrocardiograms and echocardiogram videos could augment physician interpretation.Methods and results: We chose not to train on proximate data labels such as physician over-reads of ECGs or echocardiograms but instead took advantage of electronic health record derived clinical blood pressure measurements and diagnostic consensus (often including molecular testing) among physicians in an HCM centre of excellence. Using more than 18000 combined instances of electrocardiograms and echocardiograms from 2728 patients, we developed LVH-fusion. On held-out test data, LVH-fusion achieved an F1-score of 0.71 in predicting HCM, and 0.96 in predicting HTN. In head-to-head comparison with human readers LVH-fusion had higher sensitivity and specificity rates than its human counterparts. Finally, we use explainability techniques to investigate local and global features that positively and negatively impact LVH-fusion prediction estimates providing confirmation from unsupervised analysis the diagnostic power of lateral T-wave inversion on the ECG and proximal septal hypertrophy on the echocardiogram for HCM.Conclusion: These results show that deep learning can provide effective physician augmentation in the face of a common diagnostic dilemma with far reaching implications for the prevention of sudden cardiac death.

    View details for DOI 10.1093/ehjdh/ztac033

    View details for PubMedID 36712167

  • Training in Critical Care Cardiology Within Critical Care Medicine Fellowship: A Novel Pathway. Journal of the American College of Cardiology O'Brien, C. G., Barnett, C. F., Dudzinski, D. M., Sanchez, P. A., Katz, J. N., Harold, J. G., Hennessey, E. K., Mohabir, P. K. 2022; 79 (6): 609-613

    View details for DOI 10.1016/j.jacc.2021.12.009

    View details for PubMedID 35144752

  • Editor's Choice-Prospective registry of cardiac critical illness in a modern tertiary care Cardiac Intensive Care Unit. European heart journal. Acute cardiovascular care Watson, R. A., Bohula, E. A., Gilliland, T. C., Sanchez, P. A., Berg, D. D., Morrow, D. A. 2019; 8 (8): 755-761


    The changing landscape of care in the Cardiac Intensive Care Unit (CICU) has prompted efforts to redesign the structure and organization of advanced CICUs. Few studies have quantitatively characterized current demographics, diagnoses, and outcomes in the contemporary CICU.We evaluated patients in a prospective observational database, created to support quality improvement and clinical care redesign in an AHA Level 1 (advanced) CICU at Brigham and Women's Hospital, Boston, MA, USA. All consecutive patients (N=2193) admitted from 1 January 2015 to 31 December 2017 were included at the time of admission to the CICU.The median age was 65 years (43% >70 years) and 44% of patients were women. Non-cardiovascular comorbidities were common, including chronic kidney disease (27%), pulmonary disease (22%), and active cancer (13%). Only 7% of CICU admissions were primarily for an acute coronary syndrome, which was the seventh most common individual diagnosis. The top three reasons for admission to the CICU were shock/hypotension (26%), cardiopulmonary arrest (11%), or primary arrhythmia without arrest (9%). Respiratory failure was a primary or major secondary reason for triage to the CICU in 17%. In-hospital mortality was 17.6%.In a tertiary, academic, advanced CICU, patients are elderly with a high burden of non-cardiovascular comorbid conditions. Care has shifted from ACS toward predominantly shock and cardiac arrest, as well as non-ischemic conditions, and the mortality of these conditions is high. These data may be useful to guide cardiac critical care redesign.

    View details for DOI 10.1177/2048872618789053

    View details for PubMedID 30033736

  • Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Patch in Rats With Heart Failure. The Annals of thoracic surgery Lancaster, J. J., Sanchez, P., Repetti, G. G., Juneman, E., Pandey, A. C., Chinyere, I. R., Moukabary, T., LaHood, N., Daugherty, S. L., Goldman, S. 2019; 108 (4): 1169-1177


    To treat chronic heart failure (CHF), we developed a robust, easy to handle bioabsorbable tissue-engineered patch embedded with human neonatal fibroblasts and human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). This patch was implanted on the epicardial surface of the heart covering the previously infarcted tissue.Sprague-Dawley rats (6-8 weeks old) underwent sham surgery (n = 12) or left coronary artery ligation (n = 45). CHF rats were randomized 3 weeks after ligation to CHF control with sham thoracotomy (n = 21), or a fibroblasts/hiPSC-CMs patch (n = 24) was implanted. All sham surgery rats also underwent a sham thoracotomy. At 3 weeks after randomization, hemodynamics, echocardiography, electrophysiologic, and cell survival studies were performed.Patch-treated rats had decreased (P < .05) left ventricular-end diastolic pressure and the time constant of left ventricular relaxation (Tau), increased anterior wall thickness in diastole, and improved echocardiography-derived indices of diastolic function (E/e' [ratio of early peak flow velocity to early peak LV velocity] and e'/a' [ratio of early to late peak left ventricular velocity]). All rats remained in normal sinus rhythm, with no dysrhythmias. Rats treated with the patch showed improved electrical activity. Transplanted hiPSC-CMs were present at 7 days but not detected at 21 days after implantation. The patch increased (P < .05) gene expression of vascular endothelial growth factor, angiopoietin 1, gap junction α-1 protein (connexin 43), β-myosin heavy 7, and insulin growth factor-1 expression in the infarcted heart.Epicardial implantation of a fibroblasts/hiPSC-CMs patch electrically enhanced conduction, lowered left ventricular end-diastolic pressure, and improved diastolic function in rats with CHF. These changes were associated with increases in cytokine expression.

    View details for DOI 10.1016/j.athoracsur.2019.03.099

    View details for PubMedID 31075250

  • Identification of Racial Inequities in Access to Specialized Inpatient Heart Failure Care at an Academic Medical Center. Circulation. Heart failure Eberly, L. A., Richterman, A. n., Beckett, A. G., Wispelwey, B. n., Marsh, R. H., Cleveland Manchanda, E. C., Chang, C. Y., Glynn, R. J., Brooks, K. C., Boxer, R. n., Kakoza, R. n., Goldsmith, J. n., Loscalzo, J. n., Morse, M. n., Lewis, E. F., Abel, S. n., Adams, A. n., Anaya, J. n., Andrews, E. H., Atkinson, B. n., Avutu, V. n., Bachorik, A. n., Badri, O. n., Bailey, M. n., Baird, K. n., Bakshi, S. n., Balaban, D. n., Barshop, K. n., Baumrin, E. n., Bayomy, O. n., Beamesderfer, J. n., Becker, N. n., Berg, D. D., Berman, A. N., Blum, S. M., Boardman, A. P., Boden, K. n., Bonacci, R. A., Brown, S. n., Campbell, K. n., Case, S. n., Cetrone, E. n., Charrow, A. n., Chiang, D. n., Clark, D. n., Cohen, A. J., Cooper, A. n., Cordova, T. n., Cuneo, C. N., de Feria, A. A., Deffenbacher, K. n., DeFilippis, E. M., DeGregorio, G. n., Deutsch, A. J., Diephuis, B. n., Divakaran, S. n., Dorschner, P. n., Downing, N. n., Drescher, C. n., D'Silva, K. M., Dunbar, P. n., Duong, D. n., Earp, S. n., Eckhardt, C. n., Elman, S. A., England, R. n., Everett, K. n., Fedotova, N. n., Feingold-Link, T. n., Ferreira, M. n., Fisher, H. n., Foo, P. n., Foote, M. n., Franco, I. n., Gilliland, T. n., Greb, J. n., Greco, K. n., Grewal, S. n., Grin, B. n., Growdon, M. E., Guercio, B. n., Hahn, C. K., Hasselfeld, B. n., Haydu, E. J., Hermes, Z. n., Hildick-Smith, G. n., Holcomb, Z. n., Holroyd, K. n., Horton, L. n., Huang, G. n., Jablonski, S. n., Jacobs, D. n., Jain, N. n., Japa, S. n., Joseph, R. n., Kalashnikova, M. n., Kalwani, N. n., Kang, D. n., Karan, A. n., Katz, J. T., Kellner, D. n., Kidia, K. n., Kim, J. H., Knowles, S. M., Kolbe, L. n., Kore, I. n., Koullias, Y. n., Kuye, I. n., Lang, J. n., Lawlor, M. n., Lechner, M. G., Lee, K. n., Lee, S. n., Lee, Z. n., Limaye, N. n., Lin-Beckford, S. n., Lipsyc, M. n., Little, J. n., Loewenthal, J. n., Logaraj, R. n., Lopez, D. M., Loriaux, D. n., Lu, Y. n., Ma, K. n., Marukian, N. n., Matias, W. n., Mayers, J. R., McConnell, I. n., McLaughlin, M. n., Meade, C. n., Meador, C. n., Mehta, A. n., Messenger, E. n., Michaelidis, C. n., Mirsky, J. n., Mitten, E. n., Mueller, A. n., Mullur, J. n., Munir, A. n., Murphy, E. n., Nagami, E. n., Natarajan, A. n., Nsahlai, M. n., Nze, C. n., Okwara, N. n., Olds, P. n., Paez, R. n., Pardo, M. n., Patel, S. n., Petersen, A. n., Phelan, L. n., Pimenta, E. n., Pipilas, D. n., Plovanich, M. n., Pong, D. n., Powers, B. W., Rao, A. n., Ramirez Batlle, H. n., Ramsis, M. n., Reichardt, A. n., Reiger, S. n., Rengarajan, M. n., Rico, S. n., Rome, B. N., Rosales, R. n., Rotenstein, L. n., Roy, A. n., Royston, S. n., Rozansky, H. n., Rudder, M. n., Ryan, C. E., Salgado, S. n., Sanchez, P. n., Schulte, J. n., Sekar, A. n., Semenkovich, N. n., Shannon, E. n., Shaw, N. n., Shorten, A. B., Shrauner, W. n., Sinnenberg, L. n., Smithy, J. W., Snyder, G. n., Sreekrishnan, A. n., Stabenau, H. n., Stavrou, E. n., Stergachis, A. n., Stern, R. n., Stone, A. n., Tabrizi, S. n., Tanyos, S. n., Thomas, C. n., Thun, H. n., Torres-Lockhart, K. n., Tran, A. n., Treasure, C. n., Tsai, F. D., Tsaur, S. n., Tschirhart, E. n., Tuwatananurak, J. n., Venkateswaran, R. V., Vishnevetsky, A. n., Wahl, L. n., Wall, A. n., Wallace, F. n., Walsh, E. n., Wang, P. n., Ward, H. B., Warner, L. N., Weeks, L. D., Weiskopf, K. n., Wengrod, J. n., Williams, J. N., Winkler, M. n., Wong, J. L., Worster, D. n., Wright, A. n., Wunsch, C. n., Wynter, J. S., Yarbrough, C. n., Yau, W. Y., Yazdi, D. n., Yeh, J. n., Yialamas, M. A., Yozamp, N. n., Zambrotta, M. n., Zon, R. n. 2019; 12 (11): e006214


    Racial inequities for patients with heart failure (HF) have been widely documented. HF patients who receive cardiology care during a hospital admission have better outcomes. It is unknown whether there are differences in admission to a cardiology or general medicine service by race. This study examined the relationship between race and admission service, and its effect on 30-day readmission and mortality Methods: We performed a retrospective cohort study from September 2008 to November 2017 at a single large urban academic referral center of all patients self-referred to the emergency department and admitted to either the cardiology or general medicine service with a principal diagnosis of HF, who self-identified as white, black, or Latinx. We used multivariable generalized estimating equation models to assess the relationship between race and admission to the cardiology service. We used Cox regression to assess the association between race, admission service, and 30-day readmission and mortality.Among 1967 unique patients (66.7% white, 23.6% black, and 9.7% Latinx), black and Latinx patients had lower rates of admission to the cardiology service than white patients (adjusted rate ratio, 0.91; 95% CI, 0.84-0.98, for black; adjusted rate ratio, 0.83; 95% CI, 0.72-0.97 for Latinx). Female sex and age >75 years were also independently associated with lower rates of admission to the cardiology service. Admission to the cardiology service was independently associated with decreased readmission within 30 days, independent of race.Black and Latinx patients were less likely to be admitted to cardiology for HF care. This inequity may, in part, drive racial inequities in HF outcomes.

    View details for DOI 10.1161/CIRCHEARTFAILURE.119.006214

    View details for PubMedID 31658831

    View details for PubMedCentralID PMC7183732

  • Doppler Assessment of Diastolic Function Reflect the Severity of Injury in Rats With Chronic Heart Failure. Journal of cardiac failure Sanchez, P., Lancaster, J. J., Weigand, K., Mohran, S. E., Goldman, S., Juneman, E. 2017; 23 (10): 753-761


    For chronic heart failure (CHF), more emphasis has been placed on evaluation of systolic as opposed to diastolic function. Within the study of diastology, measurements of left ventricular (LV) longitudinal myocardial relaxation have the most validation. Anterior wall radial myocardial tissue relaxation velocities along with mitral valve inflow (MVI) patterns are applicable diastolic parameters in the differentiation between moderate and severe disease in the ischemic rat model of CHF. Myocardial tissue relaxation velocities correlate with traditional measurements of diastolic function (ie, hemodynamics, Tau, and diastolic pressure-volume relationships).Male Sprague-Dawley rats underwent left coronary artery ligation or sham operation. Echocardiography was performed at 3 and 6 weeks after coronary ligation to evaluate LV ejection fraction (EF) and LV diastolic function through MVI patterns (E, A, and E/A) and Doppler imaging of the anterior wall (e' and a'). The rats were categorized into moderate or severe CHF according to their LV EF at 3 weeks postligation. Invasive hemodynamic measurements with solid-state pressure catheters were obtained at the 6-week endpoint. Moderate (N = 20) and severe CHF (N = 22) rats had significantly (P < .05) different EFs, hemodynamics, and diastolic pressure-volume relationships. Early diastolic anterior wall radial relaxation velocities as well as E/e' ratios separated moderate from severe CHF and both diastolic parameters had strong correlations with invasive hemodynamic measurements of diastolic function.Radial anterior wall e' and E/e' can be used for serial assessment of diastolic function in rats with moderate and severe CHF.

    View details for DOI 10.1016/j.cardfail.2017.08.446

    View details for PubMedID 28801075

  • Effect of lysyl oxidase inhibition on angiotensin II-induced arterial hypertension, remodeling, and stiffness. PloS one Eberson, L. S., Sanchez, P. A., Majeed, B. A., Tawinwung, S., Secomb, T. W., Larson, D. F. 2015; 10 (4): e0124013


    It is well accepted that angiotensin II (Ang II) induces altered vascular stiffness through responses including both structural and material remodeling. Concurrent with remodeling is the induction of the enzyme lysyl oxidase (LOX) through which ECM proteins are cross-linked. The study objective was to determine the effect of LOX mediated cross-linking on vascular mechanical properties. Three-month old mice were chronically treated with Ang II with or without the LOX blocker, β -aminopropionitrile (BAPN), for 14 days. Pulse wave velocity (PWV) from Doppler measurements of the aortic flow wave was used to quantify in vivo vascular stiffness in terms of an effective Young's modulus. The increase in effective Young's modulus with Ang II administration was abolished with the addition of BAPN, suggesting that the material properties are a major controlling element in vascular stiffness. BAPN inhibited the Ang II induced collagen cross-link formation by 2-fold and PWV by 44% (P<0.05). Consistent with this observation, morphometric analysis showed that BAPN did not affect the Ang II mediated increase in medial thickness but significantly reduced the adventitial thickness. Since the hypertensive state contributes to the measured in vivo PWV stiffness, we removed the Ang II infusion pumps on Day 14 and achieved normal arterial blood pressures. With pump removal we observed a decrease of the PWV in the Ang II group to 25% above that of the control values (P=0.002), with a complete return to control values in the Ang II plus BAPN group. In conclusion, we have shown that the increase in vascular stiffness with 14 day Ang II administration results from a combination of hypertension-induced wall strain, adventitial wall thickening and Ang II mediated LOX ECM cross-linking, which is a major material source of vascular stiffening, and that the increased PWV was significantly inhibited with co-administration of BAPN.

    View details for DOI 10.1371/journal.pone.0124013

    View details for PubMedID 25875748

    View details for PubMedCentralID PMC4395147